382 related articles for article (PubMed ID: 27026675)
1. Risk of Congestive Heart Failure in Early Breast Cancer Patients Undergoing Adjuvant Treatment With Trastuzumab: A Meta-Analysis.
Long HD; Lin YE; Zhang JJ; Zhong WZ; Zheng RN
Oncologist; 2016 May; 21(5):547-54. PubMed ID: 27026675
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
Leung HW; Chan AL
Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
[TBL] [Abstract][Full Text] [Related]
5. Congestive heart failure risk in patients with breast cancer treated with bevacizumab.
Choueiri TK; Mayer EL; Je Y; Rosenberg JE; Nguyen PL; Azzi GR; Bellmunt J; Burstein HJ; Schutz FA
J Clin Oncol; 2011 Feb; 29(6):632-8. PubMed ID: 21205755
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab containing regimens for early breast cancer.
Moja L; Tagliabue L; Balduzzi S; Parmelli E; Pistotti V; Guarneri V; D'Amico R
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD006243. PubMed ID: 22513938
[TBL] [Abstract][Full Text] [Related]
9. One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis.
Inno A; Barni S; Ghidini A; Zaniboni A; Petrelli F
Breast Cancer Res Treat; 2019 Jan; 173(2):247-254. PubMed ID: 30317424
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Dahabreh IJ; Linardou H; Siannis F; Fountzilas G; Murray S
Oncologist; 2008 Jun; 13(6):620-30. PubMed ID: 18586917
[TBL] [Abstract][Full Text] [Related]
11. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
Pivot X; Suter T; Nabholtz JM; Pierga JY; Espie M; Lortholary A; Khayat D; Pauporte I; Romieu G; Kramar A; Fumoleau P
Eur J Cancer; 2015 Sep; 51(13):1660-6. PubMed ID: 26163096
[TBL] [Abstract][Full Text] [Related]
12. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
14. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.
Zhou Q; Yin W; Du Y; Lu J
PLoS One; 2014; 9(1):e83646. PubMed ID: 24392090
[TBL] [Abstract][Full Text] [Related]
15. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.
Lidbrink E; Chmielowska E; Otremba B; Bouhlel A; Lauer S; Liste Hermoso M; Nüesch E; Shing M; Misra V
Breast Cancer Res Treat; 2019 Feb; 174(1):187-196. PubMed ID: 30506110
[TBL] [Abstract][Full Text] [Related]
16. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis.
Chen T; Xu T; Li Y; Liang C; Chen J; Lu Y; Wu Z; Wu S
Cancer Treat Rev; 2011 Jun; 37(4):312-20. PubMed ID: 20952131
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
18. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
Valachis A; Nearchou A; Polyzos NP; Lind P
Int J Cancer; 2013 Nov; 133(9):2245-52. PubMed ID: 23629633
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
20. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
